A Brixadi treatment program gives you a structured, provider-administered path through opioid use disorder, built around an extended-release buprenorphine injection rather than a daily pill or film. Understanding what the program actually includes, from the first appointment through ongoing monitoring, helps you walk in prepared rather than guessing.
What Brixadi Is and How It Works
Brixadi is an FDA-approved subcutaneous extended-release buprenorphine injection indicated for the treatment of opioid use disorder. In plain terms, buprenorphine binds to the same opioid receptors targeted by heroin, fentanyl, and prescription painkillers, reducing cravings and blocking withdrawal symptoms without producing a euphoric high. The extended-release formulation delivers that medication gradually from beneath the skin over days or weeks, rather than requiring a dose every morning.
A 2020 SAMHSA analysis found that patients receiving buprenorphine-based medication-assisted treatment were significantly more likely to remain in treatment at six and twelve months compared to those receiving no medication. Retention is what makes the rest of treatment possible, which is why the delivery method matters as much as the molecule.
How Brixadi Differs from Suboxone and Sublocade
Suboxone is a daily sublingual film you dissolve under your tongue. Sublocade is a once-monthly subcutaneous injection. Brixadi occupies different ground: it is the only subcutaneous buprenorphine formulation available in both weekly and monthly dosing schedules. That flexibility is clinically meaningful. Early in treatment, a weekly injection lets your provider assess how you’re responding and adjust quickly. As you stabilize, a monthly schedule reduces how often you need to come in.
The practical difference is also behavioral. With a daily film, you make a medication decision every single day. With Brixadi, a provider administers the injection in the office, and the medication is already in your system when you leave. There is no dose to remember, no film to store at home, and no opportunity for the medication to be diverted or misused.
What the First Appointment Actually Looks Like
One of the most common misconceptions about starting buprenorphine is that you need to spend days in withdrawal before your first dose. That was true of older induction protocols, but research has changed practice. A 2022 study published in JAMA Network Open demonstrated that low-dose buprenorphine induction, sometimes called a Bernese method approach, allows patients to begin treatment without a prolonged opioid-free waiting period, reducing the barrier to getting started.
For Brixadi specifically, a clinician administers the injection subcutaneously, typically into the upper arm or abdomen. The appointment itself is short. You do not need to plan for a long procedure or extended observation period in most cases. The medication is active before you walk out.
The concrete step before that first appointment: be honest with your provider about your last opioid use, the substance, the amount, and the timing. That information directly shapes your starting dose and your induction approach. Withholding it does not protect you; it limits your provider’s ability to set you up correctly from day one.
The Dosing Schedule and What It Means for Your Life
The choice between weekly and monthly injections is not arbitrary. It reflects where you are in treatment. Early on, weekly appointments give your care team more frequent contact, which matters when you’re navigating the most unstable period of recovery. Once you’ve established consistency, moving to monthly dosing reduces your clinic visits to twelve per year.
A 2021 study published in Drug and Alcohol Dependence found that long-acting injectable buprenorphine produced higher treatment retention rates compared to daily oral formulations, particularly among patients who had struggled with adherence in prior treatment episodes. The mechanism is straightforward: fewer decisions means fewer points of failure.
If transportation, work schedules, or childcare make frequent clinic visits difficult, that is worth raising at your first appointment. If you want to understand how extended-release buprenorphine on a weekly schedule works in practice, that context helps you arrive at the dosing conversation prepared. Ask your provider which schedule fits your current situation, not just which one sounds easiest on paper.
The Counseling and Support Components
Brixadi is medication, not a complete treatment program on its own. A well-structured program pairs the injection with behavioral health support, including individual counseling, group sessions, or both. The medication handles the neurochemistry. Counseling addresses the patterns.
A 2019 NIDA-funded trial found that patients receiving both medication-assisted treatment and counseling had significantly better outcomes on measures of opioid use and quality of life compared to those receiving medication alone. What counseling adds in practice: structured work on coping skills, identification of relapse triggers, and space to address the life circumstances that intersect with opioid use disorder.
Before committing to a program, ask what behavioral health services are included and how frequently you’re expected to attend. Some programs have counselors on-site; others coordinate with outside providers. Knowing which model you’re entering shapes your schedule and your expectations.
Managing Co-Occurring Mental Health Conditions
A 2022 SAMHSA report found that approximately 9.2 million adults in the United States had co-occurring mental illness and a substance use disorder in the previous year. Depression, anxiety, and trauma are common companions to opioid use disorder, not separate problems that resolve once the opioid use stops.
A well-structured Brixadi program screens for these conditions at intake rather than treating OUD in isolation. When you call to schedule your first appointment, ask directly whether the program includes mental health screening and whether a prescriber at the same practice can address both conditions. Coordinated care under one roof is meaningfully different from being referred out and left to manage the coordination yourself.
Insurance Coverage and Cost
Medicaid covers Brixadi in Maryland, making it accessible to a large portion of people seeking treatment in the state. For patients with commercial insurance, the BRIXADI Copay Savings Program offers $0 per injection for eligible patients. Brixadi is distributed through a REMS-certified specialty pharmacy network, meaning your provider orders the medication through that system rather than sending you to a standard retail pharmacy.
A 2021 Health Affairs study identified cost as one of the primary reasons patients discontinue medication-assisted treatment prematurely. Understanding your coverage before your first appointment removes that barrier from the equation.
The action: call your insurance before the appointment, confirm whether prior authorization is required, and ask your provider’s office whether they handle the prior auth process on your behalf. Many practices that work with Medicaid patients in Maryland manage the administrative side as a standard part of intake. If you’re looking for a clinic in Maryland that navigates this process with you, that coordination capacity is worth asking about specifically.
What Happens If You Don’t Have Insurance
If you are uninsured, tell the intake coordinator at your first call. That is the right time to have that conversation. Programs structured around Medicaid patients have experience connecting uninsured patients to state-funded treatment slots, sliding-scale fee arrangements, and manufacturer assistance programs. Braeburn, the maker of Brixadi, offers a patient assistance program for those who qualify.
The intake call is not just scheduling. It is the start of the coverage conversation. Being direct about your situation means the team can identify your pathway before you arrive, rather than after.
What Progress Looks Like Over Time
A 2020 study published in the New England Journal of Medicine found that extended buprenorphine maintenance was associated with sustained reductions in opioid use over a 24-week period, with benefits continuing as long as treatment was maintained. The takeaway from that evidence: there is no universal right duration for a Brixadi program. Stability is the goal, and stability looks different for each person.
Over time, your provider monitors injection site reactions, craving frequency, mental health status, and overall functioning. The markers that matter most are not clinical data points on a chart. They are concrete: fewer cravings, more consistent daily functioning, and an improving ability to manage the circumstances that made opioid use a problem in the first place.
At each visit, ask your provider what metric they are using to assess your progress. A specific answer to that question helps you understand what stability actually looks like for your treatment, rather than waiting for someone else to tell you when you’re doing well.
Starting the Process This Week
Call a Maryland Brixadi provider, tell the intake coordinator your insurance status and the details of your recent opioid use, and ask how quickly the first injection appointment can be scheduled. If you’re not sure where to start finding a provider near you, the intake call itself is the first step. You do not need to have everything figured out before you make that call.
The intake process at programs offering injectable buprenorphine is structured to meet you where you are. The call is the hardest part. Make it this week.